129 related articles for article (PubMed ID: 2204207)
1. [Insulin needs of insulin-dependent diabetics during biostator control and subcutaneous use of insulin].
Petkova M; Khristov V; Tsanev A
Vutr Boles; 1990; 29(1):74-7. PubMed ID: 2204207
[TBL] [Abstract][Full Text] [Related]
2. Studies on the clinical importance of the constants used in the algorithm of an artificial B-cell (Biostator).
Ratzmann KP; Jutzi E; Albrecht G
Z Exp Chir Transplant Kunstliche Organe; 1983; 16(5):270-6. PubMed ID: 6359740
[TBL] [Abstract][Full Text] [Related]
3. [An improvement in insulin efficacy in patients with type-1 diabetes mellitus following treatment using an insulin infusion pump].
Borisova AM; Koev D; Kirilov G
Vutr Boles; 1989; 28(1):74-7. PubMed ID: 2662610
[TBL] [Abstract][Full Text] [Related]
4. [Use of the artificial endocrine pancreas in the clinic].
Tsanev A; Zlateva S; Khristov V; Petkova M
Vutr Boles; 1985; 24(6):107-11. PubMed ID: 4095982
[TBL] [Abstract][Full Text] [Related]
5. [Dynamic changes in the hemostatic indices of diabetics during biostator control].
Petkova M; Kamenov V; Tsanev A
Vutr Boles; 1989; 28(5):41-5. PubMed ID: 2482584
[TBL] [Abstract][Full Text] [Related]
6. Insulin treatment and state of control before, during, and after connection to a glucose controlled insulin infusion system (Biostator).
Christiansen JS; Svendsen PA; Deckert T
Horm Metab Res Suppl; 1979; (8):131-4. PubMed ID: 395069
[TBL] [Abstract][Full Text] [Related]
7. [Assessment of metabolic control and safety of continuous subcutaneous insulin infusion in prepubertal children with type 1 diabetes mellitus].
Minkina-Pedras M; Jarosz-Chobot P; Małecka-Tendera E; Deja G
Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2005; 11(3):171-6. PubMed ID: 16232370
[TBL] [Abstract][Full Text] [Related]
8. Comparison of 24-hour insulin requirements in IDDM patients during control by an artificial betacell and during conventional therapy.
Christiansen JS; Svendsen PA; Mathiesen E; Rubin P; Deckert T
Horm Metab Res; 1981 Oct; 13(10):537-41. PubMed ID: 7028586
[TBL] [Abstract][Full Text] [Related]
9. Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion.
Raz I; Weiss R; Yegorchikov Y; Bitton G; Nagar R; Pesach B
Clin Ther; 2009 May; 31(5):980-7. PubMed ID: 19539098
[TBL] [Abstract][Full Text] [Related]
10. Long-term improvement in metabolic control of unstable type I diabetes by s.c. insulin injection patterns based on the dose profiles required by bed-side artificial beta-cell.
Bombor H; Bruns W; Ratzmann KP; Jutzi E; Albrecht G; Michaelis D; Fischer U
Exp Clin Endocrinol; 1984 Apr; 83(2):143-51. PubMed ID: 6373316
[TBL] [Abstract][Full Text] [Related]
11. A comparison of premeal subcutaneous insulin infusion and injection in type I diabetic patients under continuous basal subcutaneous insulin delivery.
Navascués I; Kerner W; Pfeiffer EF
Life Support Syst; 1985; 3(3):263-7. PubMed ID: 3900596
[TBL] [Abstract][Full Text] [Related]
12. Improvement of artificial endocrine pancreas (Biostator; GCIIS) performance combining feedback controlled insulin administration with a pre-programmed insulin infusion.
Calabrese G; Bueti A; Zega G; Giombolini A; Bellomo G; Antonella MA; Massi-Benedetti M; Brunetti P
Horm Metab Res; 1982 Oct; 14(10):505-7. PubMed ID: 6757081
[TBL] [Abstract][Full Text] [Related]
13. Comparison of a perfusion syringe (Mill Hill Infusor) and a glucose-controlled insulin infusion system in the regulation of diabetes mellitus.
Stavljenić A; Granić M; Topić B; Skrabalo Z
Horm Metab Res Suppl; 1979; (8):207-11. PubMed ID: 395083
[TBL] [Abstract][Full Text] [Related]
14. [Study of the "dawn phenomenon" using an artificial endocrine pancreas].
Khristov V; Petkova M; Tsanev A
Vutr Boles; 1988; 27(6):35-8. PubMed ID: 3247701
[TBL] [Abstract][Full Text] [Related]
15. Fasting and postprandial plasma glucose and peripheral insulin levels in insulin-dependent diabetes mellitus and non-insulin-dependent diabetes mellitus subjects during continuous intraperitoneal versus subcutaneous insulin delivery.
Hermans MP; van Ypersele de Strihou M; Ketelslegers JM; Squifflet JP; Buysschaert M
Transplant Proc; 1995 Dec; 27(6):3329-30. PubMed ID: 8539974
[No Abstract] [Full Text] [Related]
16. [Remission of diabetes during conventional insulin therapy or therapy controlled by use of an artificial pancreas].
Mirouze J; Selam JL; Pham TC; Mendoza E
Sem Hop; 1979 Feb 18-25; 55(7-8):354-9. PubMed ID: 220725
[TBL] [Abstract][Full Text] [Related]
17. Reduction of post-prandial insulin needs by pectin as assessed by the artificial pancreas in insulin-dependent diabetics.
Poynard T; Slama G; Tchobroutsky G
Diabete Metab; 1982 Sep; 8(3):187-9. PubMed ID: 6754491
[TBL] [Abstract][Full Text] [Related]
18. Subcutaneous insulin substitution in insulin-dependent diabetes mellitus. Pharmacokinetic and pharmacodynamic studies.
Olsson PO
Acta Med Scand Suppl; 1987; 718():1-78. PubMed ID: 3321929
[TBL] [Abstract][Full Text] [Related]
19. In Type 1 diabetic patients with good glycaemic control, blood glucose variability is lower during continuous subcutaneous insulin infusion than during multiple daily injections with insulin glargine.
Bruttomesso D; Crazzolara D; Maran A; Costa S; Dal Pos M; Girelli A; Lepore G; Aragona M; Iori E; Valentini U; Del Prato S; Tiengo A; Buhr A; Trevisan R; Baritussio A
Diabet Med; 2008 Mar; 25(3):326-32. PubMed ID: 18307459
[TBL] [Abstract][Full Text] [Related]
20. Postprandial insulin profiles with implantable pump therapy may explain decreased frequency of severe hypoglycemia, compared with intensive subcutaneous regimens, in insulin-dependent diabetes mellitus patients.
Nathan DM; Dunn FL; Bruch J; McKitrick C; Larkin M; Haggan C; Lavin-Tompkins J; Norman D; Rogers D; Simon D
Am J Med; 1996 Apr; 100(4):412-7. PubMed ID: 8610727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
